ASX:AVE

Avecho Biotechnology Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive AVE News and Ratings via Email

Sign-up to receive the latest news and ratings for Avecho Biotechnology and its competitors with MarketBeat's FREE daily newsletter.


About Avecho Biotechnology

Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally. The company operates through Production, Human Health, and Other segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 is based in Clayton, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Avecho Biotechnology (ASX:AVE) Frequently Asked Questions

What stocks does MarketBeat like better than Avecho Biotechnology?

Wall Street analysts have given Avecho Biotechnology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avecho Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avecho Biotechnology's next earnings date?

Avecho Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 26th 2021.
View our earnings forecast for Avecho Biotechnology.

Who are Avecho Biotechnology's key executives?

Avecho Biotechnology's management team includes the following people:
  • Dr. Roksan Libinaki, COO & GM of Animal Health & Nutrition
  • Dr. Paul Gavin, CEO & Chief Scientific Officer
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Company Sec. & CFO (Age 48)

Who are some of Avecho Biotechnology's key competitors?

Some companies that are related to Avecho Biotechnology include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS) and Amplia Therapeutics (ATX).
View all of AVE's competitors.

What is Avecho Biotechnology's stock symbol?

Avecho Biotechnology trades on the ASX under the ticker symbol "AVE."

How much money does Avecho Biotechnology make?

Avecho Biotechnology has a market capitalization of $0.00 and generates $384,627.00 in revenue each year.

What is Avecho Biotechnology's official website?

The official website for Avecho Biotechnology is avecho.com.au.

How can I contact Avecho Biotechnology?

The company can be reached via phone at 61 3 9002 5000.


This page was last updated on 7/29/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.